Aldosterone in clinical nephrology - Old hormone, new questions

Nephrology Dialysis Transplantation

Volumn 24, Issue 8, 2009, Pages 2316-2321

  Becker, Gavin J ^a   Hewitson, Tim D ^a   Chrysostomou, Anastasia ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Aldosterone; Eplerenone; Hypertension; Proteinuria; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; SPIRONOLACTONE;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; GLOMERULUS FILTRATION RATE; HORMONE ACTION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; HUMANS; HYPERTENSION; KIDNEY DISEASES; NEPHROLOGY; SPIRONOLACTONE;

EID: 67651083499     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp256     Document Type: Editorial

References (60)

1. Ritz E, Tomaschitz A. Aldosterone a vasculotoxic agent-novel functions for an old hormone. Nephrol Dial Transplant 2009; 24: 2302-2305
2. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492
3. Ye P, Kenyon CJ, Mackenzie SM et al. The aldosterone synthase (CYP11B2) and 11 beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart. Endocrinology 2005; 146: 5287-5293
4. Funder JW. Cardiac synthesis of aldosterone: going, going, gone . . .? Endocrinology 2004; 145: 4793-4795
5. Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 2005; 46: 584-590
6. Nishikawa T, Suematsu S, Saito J et al. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol 2005; 96: 309-316
7. Funder JW. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology 2006; 147: 5564-5567
8. Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-2263
9. Uhrenholt TR, Schjerning J, Hansen PB et al. Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res 2003; 93: 1258-1266
10. Nagai Y, Miyata K, Sun GP et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 2005; 46: 1039-1045
11. Nishiyama A, Yao L, Fan Y et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005; 45: 710-716
12. Shibata S, Nagase M, Yoshida S et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-364
13. Wakisaka M, Spiro MJ, Spiro RG. Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen. Diabetes 1994; 43: 95-103
14. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 2008; 19: 1459-1462
15. Chrysostomou A, Becker GJ. Spironalactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Eng J Med 2001; 345: 925-926
16. Bomback AS, Kshirsagar AV, Amamoo AM et al. Change in proteinuria after adding aldosterone blockers toACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.Am J Kidney Dis 2008; 51: 199-211
17. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123
18. Epstein M, Williams GH, Weinberger M et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951
19. Chrysostomou A, Pedagogos E, MacGregor L et al. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-termangiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262
20. van den Meiracker AH, Baggen RG, Pauli S et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24: 2285-2292
21. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49
22. Tylicki L, Rutkowski P, Renke Met al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. AmJ Kidney Dis 2008; 52: 486-493
23. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836
24. Ribstein J, du CG, Fesler P et al. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005; 16: 1320-1325
25. Sechi LA, Novello M, Lapenna R et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-2645
26. Hatakeyama H, Miyamori I, Fujita T et al. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994; 269: 24316-24320
27. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992; 20: 67-73
28. Buter H, Hemmelder MH, Navis G et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13: 1682-1685
29. Brown NJ, Nakamura S, Ma L et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219-1227
30. Lai L, Chen J, Hao CM et al. Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway inmesangial cells. Biochem Biophys Res Commun 2006; 348: 70-75
31. Juknevicius I, Segal Y, Kren S et al. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 2004; 286: F1059-F1062
32. Yokoi H, Mukoyama M, Sugawara A et al. Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. Am J Physiol 2002; 282: F933-F942
33. Nishiyama A, Yao L, Nagai Y et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004; 43: 841-848
34. Furumatsu Y, Nagasawa Y, Tomida K et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008; 31: 59-67
35. Padfield P. Primary aldosteronism: the case against screening. Nat Clin Pract Nephrol 2007; 3: 580-581
36. Gordon RD, StowasserM. Primary aldosteronism: the case for screening. Nat Clin Pract Nephrol 2007; 3: 582-583
37. Gordon RD, Stowasser M, Tunny TJ et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318
38. Fardella CE, Mosso L, Gomez-Sanchez C et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867
39. Lim PO, Dow E, Brennan G et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311-315
40. Mosso L, Carvajal C, Gonzalez A et al. Primary aldosteronism and hypertension disease. Hypertension 2003; 42: 161-165
41. Strauch B, Zelinka T, Hampf M et al. Prevalence of primary hyperaldoseronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17: 349-352
42. Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000; 54(Suppl 1): 83s-85s
43. Vasan RS, Evans JC, Larson MG et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41
44. Newton-Cheh C, Guo CY, Gona P et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2008; 49: 846-856
45. Weinberger MH, Roniker B, Krause SL et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709-716
46. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension.AmJHypertens 2003; 16: 925-930
47. Sharabi Y, Adler E, Shamis A et al. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006; 19: 750-755
48. Ouzan J, Perault C, Lincoff AM et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am JHypertens 2002; 15: 333-339
49. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007; 25: 891-894
50. Johnston LC, Grieble HG. Treatment of arterial hypertensive disease with diuretics. V. Spironolactone, an aldosterone antagonist. Arch Intern Med 1967; 119: 225-231
51. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-845
52. Prisant LM, Krum H, Roniker B et al. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J Clin Pharmacol. 2003; 43: 1203-1210
53. Goodfriend TL. Treating resistant hypertension with a neglected old drug. Hypertension 2007; 49: 763-764
54. Wenzel U. Aldosterone and progression of renal disease. Curr Opin Nephrol Hypertens 2008; 17: 44-50
55. Saha C, Eckert GJ, Ambrosius WT et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46: 481-487
56. Schepkens H, Vanholder R, Billiouw JM et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am JMed 2001; 110: 438-441
57. Rachmani R, Slavachevsky I, Amit M et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21: 471-475
58. Rossing K, Schjoedt KJ, Smidt UM et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112
59. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542
60. Saklayen MG, Gyebi LK, Tasosa J et al. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med 2008; 56: 714-719